Commentary Open Access
Volume 7 | Issue 1 | DOI: https://doi.org/10.46439/biomedres.7.083
Leukemia stem cells in acute myeloid leukemia: biology, therapeutic resistance, and barriers to durable remission
Giovannino Silvestri1,2,3,*
- 1Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA
- 2Member, Cancer Therapeutics Program, Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA
- 3Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA
Corresponding Author
Giovannino Silvestri, gsilvestri@ihv.umaryland.edu
Received Date: February 19, 2026
Accepted Date: April 17, 2026
Silvestri G. Leukemia stem cells in acute myeloid leukemia: biology, therapeutic resistance, and barriers to durable remission. J Biomed Res. 2026;7(1):41-45.
Copyright: © 2026 Silvestri G. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Measurable residual disease as a surrogate endpoint for overall survival in acute myeloid leukemia: a call to action
The standardization and implementation of new endpoints are crucial for the development of novel therapeutic agents. These endpoints help streamline clinical development while maintaining high standards of care for innovative treatments, ultimately leading to improved patient outcomes.
FHIT as a biomarker for early screening of adult T-cell leukemia
Adult T-cell leukemia (ATL) is an incurable leukemia deriving from human T-cell leukemia virus (HTLV-I) infected cells. In our most recent study, we discovered that methylation of the tumor suppressor, fragile histidine triad gene (FHIT), exists in the majority of acute and chronic ATL patients. Methylation was seen in non-tumorigenic cells, in cells with low levels of HTLV-I integrated DNA, in longitudinal samples from HTLV
Development of an error-corrected next-generation sequencing method for the quantification of hotspot cancer driver mutations
Low-frequency somatic mutations accumulate in normal tissues throughout life and contribute to cancer initiation, yet their detection is limited by the sensitivity of conventional sequencing methods. We describe CarcSeq, an error-corrected, targeted next-generation sequencing platform developed to quantify rare cancer driver mutations (CDMs) at variant allele frequencies as low as ~10-4. CarcSeq integrates high-fidelity amplification, unique molecular identifiers, and single-strand consensus sequencing to accurately measure mutant frequency (MF) across a curated panel of sequences encompassing recurrent oncogene and tumor suppressor hotspots.
Leukemia stem cells in acute myeloid leukemia: biology, therapeutic resistance, and barriers to durable remission
Acute myeloid leukemia (AML) is a biologically heterogeneous hematologic malignancy characterized by uncontrolled proliferation of immature myeloid cells and disruption of normal hematopoiesis. Despite major advances in genomic classification and the development of targeted therapies, long-term survival remains limited for many patients due to relapse and treatment resistance [1–3].